65,437 trials
Aphakia · Corneal Astigmatism
Primary: Percentage of Eyes With ≤ 0.25 Diopter (D) Absolute Refractive Cylinder at Visit 3/3A (Day 30-60) — 90.2 percentage of eyes — p=<0.0001
Opioid Addiction
Primary: Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category — 0.315; 0.328; 0.384; 0.394 Mean default mode network (DMN) z-scores
Tobacco Use · Tobacco Smoking · Tobacco Use Cessation
Primary: Acceptability 1: Participant Rating of Usefulness of Intervention — 6.62; 6.58 units on a scale
Kidney Transplant
Primary: The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups. — 52.45; 57.35 mL/min/1.73m2 — p=0.099
Breast Lift
Primary: Measurements of Distance (cm) Between Breast Area Reference Points (Nipple to Nipple) — 20.6 centimeters
Rheumatoid Arthritis Interstitial Lung Disease
Primary: Number of Participants Who Developed Any Element of the Composite Endpoint — 7; 9 Participants
Asthma
Primary: Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With…
Pain Relief · Adverse Events
Primary: Mean Change in Numeric Pain Score (NPS) From First to Last Dose — 2.2; 2.5 score on a scale
Ductal Breast Carcinoma In Situ · Estrogen Receptor Positive · Invasive Breast Carcinoma
Primary: Number of Participants With Adverse Events Greater Than Grade 2 Serious Toxicity Rate, Defined as Toxicity Greater Than Grade 2 Using Common Terminology Criteria for…
Depressive Disorder, Major
Primary: Time to All-Cause Discontinuation of Study Drug — NA; NA days — p=0.5355
Head and Neck Cancer · Oral Mucositis
Primary: Incidence of Treatment Emergent AE's — 36; 12; 33; 35 Participants
Opioid Use, Unspecified
Primary: Average Weekly Milligram Morphine Equivalent (MME) — 34.62; 22.37; NA Weekly MME per clinician — p=0.43
Obesity · PreDiabetes
Primary: Change in Flow-mediated Dilation — 0.71; 2.06; 1.24; 0.48 Percentage
Prehypertension · Hypertension, Stage I
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1; 1; 4; 0 Participants
Influenza
Primary: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection — 57.1; 34.7; 45.9; 26.0 percentage of participants